Accessibility Menu
CVRx logo

CVRx(NASDAQ) CVRX

Market Cap$131.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-82%
5 Year-75%
1 Year-40%
1 Month-17%
$5.36
+8.28%
+0.41Today
CVRx last closing stock price
MetricPriceDate
Last closeUSD 4.952026-07-29
CVRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.75%USD 5.092026-07-22
1 month-16.67%USD 5.942026-06-29
3 month-34.09%USD 7.512026-04-30
Year to date-30.28%USD 7.102025-12-31
1 year-40.07%USD 8.262025-07-29
3 year-72.13%USD 17.762023-07-28
5 year-74.92%USD 19.742021-07-30
Since inception-82.32%USD 28.002021-06-30

CVRx Financials at a Glance

Market Cap

$131.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$59.07M

Net Income (TTM)

-$52.66M

EPS (TTM)

-$2.01

P/E Ratio

-2.46

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$5.36

Volume

268,691

Open

$5.20

Previous Close

$5.38

Daily Range

$4.93 - $5.39

52-Week Range

$4.37 - $11.30

Estimated Earnings Date

Aug 6, 2026

CVRX News

what-does-johnson-and-johnson-own-infographic

What Companies Does Johnson & Johnson Own?

Matt DiLalloDec 30, 2025
Foolcom-Featured.png

CVRx (CVRX) Q2 Revenue Jumps 15%

Motley Fool Markets TeamAug 4, 2025

CVRX: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CVRx

CVRx makes devices for people with heart failure. Its main product, Barostim, helps patients feel better by sending electrical signals to nerves in the neck. This technology aims to improve daily life for those with serious heart conditions.

Gadgets That Matter: Products and Services

  • Barostim (100% of revenue): An implantable device for heart failure patients, sending electrical pulses to nerves in the neck to improve symptoms.
  • Implantable Pulse Generator: The main part of Barostim, placed under the skin to deliver therapy.
  • Stimulation Lead: A wire connecting the generator to the carotid artery, where it stimulates nerves.
  • Clinician Programmer: A wireless tool doctors use to adjust Barostim settings for each patient.
  • Surgical Accessories: Tools and parts needed for safe and effective device implantation.

Growth Spurts: Expansion and Milestones

  • Expanded U.S. direct sales force from 38 to 48 territories in 2024.
  • Increased U.S. implanting centers from 178 to 223 in 2024.
  • Added 7,615 sq. ft. to Minneapolis headquarters in 2023.
  • Secured improved U.S. reimbursement rates for Barostim in 2025.
  • Maintained distribution in Europe through direct sales and independent partners since product launch.

Why CVRx Stands Out (Without Bragging)

CVRx operates in both the U.S. and Europe, using direct sales and distributors. Its Barostim device is the first of its kind approved for heart failure patients, offering a minimally invasive option. The company supports its product with clinical studies and a strong patent portfolio.

Five Things You Need to Know

  • Revenue was $51.3 million in 2024, up 31% from 2023.
  • U.S. sales made up 92% of 2024 revenue; Europe contributed 8%.
  • Gross margin held steady at 84% in 2024 and 2023.
  • Net loss was $60.0 million in 2024, up from $41.2 million in 2023.

Bottom Line

CVRx has grown by focusing on a single, innovative heart failure device. The company faces ongoing losses but continues to expand its reach and clinical support.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

223

CEO

Kevin Hykes, MBA

Website

www.cvrx.com

Headquarters

Minneapolis, MN 55445, US

CVRX Financials

Key Financial Metrics (TTM)

Gross Margin

85.53%

Operating Margin

-84.62%

Net Income Margin

-89.15%

Return on Equity

-120.77%

Return on Capital

-56.89%

Return on Assets

-52.80%

Earnings Yield

-40.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$131.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

26.54M

Volume

268.69K

Avg. Volume

314.57K

Financials (TTM)

Gross Profit

$50.52M

Operating Income

-$49.99M

EBITDA

-$45.97M

Operating Cash Flow

-$39.57M

Capital Expenditure

-$588.00K

Free Cash Flow

-$40.16M

Cash & ST Invst.

$72.30M

Total Debt

$59.40M

CVRx Performance Analysis

CVRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 22,469,00072.4%
20232023-12-31USD 39,295,00074.9%
20242024-12-31USD 51,292,00030.5%
20252025-12-31USD 56,651,00010.4%
CVRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.1%
Q32025-09-308.1%
Q42025-12-319.1%
Q12026-03-31-7.8%
CVRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.02-4.5%
20232023-12-31USD -1.99-1.6%
20242024-12-31USD -2.6533.7%
20252025-12-31USD -2.04-23.0%
CVRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.5%
Q32025-09-3014.0%
Q42025-12-316.1%
Q12026-03-31-8.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$14.77M

+19.6%

Gross Profit

$12.88M

+24.9%

Gross Margin

87.22%

N/A

Market Cap

$131.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$589.03K

N/A

Employees

223

N/A

Net Income

-$13.12M

+4.7%

EBITDA

-$11.36M

+6.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$72.30M

-29.6%

Total Debt

$59.40M

+17.8%

Accounts Receivable

$9.10M

+1.0%

Inventory

$12.40M

+6.3%

Long Term Debt

$59.03M

+17.8%

Short Term Debt

$361.00K

+24.5%

Return on Assets

-52.80%

N/A

Return on Invested Capital

-55.39%

N/A

Free Cash Flow

-$12.29M

+4.6%

Operating Cash Flow

-$12.16M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTRXQuanterix Corporation
$3.52+4.14%
PRQRProQR Therapeutics N.V.
$1.78+2.89%
NNOXNano-X Imaging Ltd.
$0.97+10.01%
OMIOwens & Minor, Inc.
$2.68+8.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About CVRX

What is the current price of CVRx?

CVRx is trading at $5.38 per share.

What is the 52-week range for CVRx?

Over the past 52 weeks, CVRx has traded between $4.37 and $11.30.

How much debt does CVRx have?

As of the most recent reporting period, CVRx reported total debt of $59.40M.

How much cash does CVRx have on hand?

CVRx reported $72.30M in cash and cash equivalents in its most recent financial results.

What is CVRx’s dividend yield?

CVRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services